Why the communicable/non-communicable disease dichotomy is problematic for public health control strategies: Implications of multimorbidity for health systems in an era of health transition

International Health

Volumn 7, Issue 6, 2015, Pages 390-399

  Oni, Tolu ^a   Unwin, Nigel ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Co morbidity; Communicable disease; Health transition; Infectious disease; Low and middle income countries; Non communicable disease

Indexed keywords

ANTIRETROVIRUS AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE DEFECT; COMMUNICABLE DISEASE; COMORBIDITY; DIETARY INTAKE; DISEASE PREDISPOSITION; EPIDEMIC; EPILEPSY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; NON COMMUNICABLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL HEALTH; PHYSICAL ACTIVITY; POPULATION DYNAMICS; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RURAL HEALTH CARE; SMOKING; SOCIOECONOMICS; SYSTEMATIC REVIEW; TUBERCULOSIS; URBANIZATION; ADULT; COMMUNICABLE DISEASES; HEALTH CARE DELIVERY; MIDDLE AGED; PUBLIC HEALTH SERVICE;

ADULT; CHRONIC DISEASE; COMMUNICABLE DISEASES; COMORBIDITY; DELIVERY OF HEALTH CARE; HEALTH TRANSITION; HUMANS; MIDDLE AGED; PUBLIC HEALTH ADMINISTRATION;

EID: 84944466383     PISSN: 18763413     EISSN: 18763405     Source Type: Journal    
DOI: 10.1093/inthealth/ihv040     Document Type: Article

References (103)

1. World Bank Group. Data. Country and Lending Groups. http://data. worldbank.org/about/country-and-lending-groups [accessed 29 March 2015.
2. Setel PW, Saker L, Unwin N et al. Is it time to reassess the categorization of disease burdens in low-income countries? Am J Public Health 2004;94:384.
3. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Q 2005;83:731-57.
4. Nelson MC, Rogers J. The epidemiologic transition revisited, or what happenes if we look beneath the surface? Health Transit Rev 1997;7:235-55.
5. Santosa A, Wall S, Fottrell E et al. The development and experience of epidemiological transition theory over four decades: a systematic review. Glob Health Action 2014;7:23574.
6. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J 2009;26:91-108.
7. WHO. Global Tuberculosis Report 2014. Geneva: World Health Organization; 2014.
8. Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol 2014;2:730-9.
9. WHO. Global Strategy and Targets for Tuberculosis Prevention, Care, and Control After 2015. WHO 67th World Health Assembly 2014. Geneva: World Health Organization; 2014.
10. Patra J, Jha P, Rehm J, Suraweera W. Tobacco smoking, alcohol drinking, diabetes, low body mass index and the risk of self-reported symptoms of active tuberculosis: individual participant data (IPD) meta-analyses of 72,684 individuals in 14 high tuberculosis burden countries. PLoS ONE 2014;9:e96433.
11. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
12. Stevenson CR, Critchley JA, Forouhi NG et al. Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn 2007;3:228-45.
13. Riza AL, Pearson F, Ugarte-Gil C et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol 2014;2:740-53.
14. Faurholt-Jepsen D, Range N, Praygod G et al. Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania. PLoS ONE 2011;6:e24215.
15. Baker MA, Harries AD, Jeon CY et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.
16. International Diabetes Federation. Diabetes Atlas. Give edition. http://www.idf.org/diabetesatlas [accessed 17 November 2013].
17. Van Crevel R, Dockrell HM. TANDEM: understanding diabetes and tuberculosis. Lancet Diabetes Endocrinol 2014;2:270-2.
18. Lee C-H, Lee M-C, Shu C-C et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis 2013;13:194.
19. Inghammar M, Ekbom A, Engström G et al. COPD and the risk of tuberculosis--a population-based cohort study. PLoS ONE 2010;5: e10138.
20. Lin H-H, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med 2007;4:e20.
21. Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration 2013;86:76-85.
22. Pasipanodya JG, Miller TL, VecinoMet al. Pulmonary impairment after tuberculosis. Chest 2007;131:1817-24.
23. Willcox PA, Ferguson AD. Chronic obstructive airways disease following treated pulmonary tuberculosis. Respir Med 1989;83:195-8.
24. Hnizdo E, Singh T, Churchyard G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary tuberculosis following treatment. Thorax 2000;55:32-8.
25. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010;15:623-8.
26. Maguire GP, Anstey NM, Ardian M et al. Pulmonary tuberculosis, impaired lung function, disability and quality of life in a high-burden setting. Int J Tuberc Lung Dis 2009;13:1500-6.
27. Ehrlich RI, White N, Norman R et al. Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis 2004;8:369-76.
28. Barsoum RS. Chronic kidney disease in the developing world. N Engl J Med 2006;354:10.
29. Hussein M, Mooij J. Tuberculosis and chronic renal disease. Saudi J Kidney Dis Transpl 2002;320-30.
30. Venkata RK, Kumar S, Krishna RP et al. Tuberculosis in chronic kidney disease. Clin Nephrol 2007;67:217-20.
31. Ates G, Yildiz T, Danis R et al. Incidence of tuberculosis disease and latent tuberculosis infection in patients with end stage renal disease in an endemic region. Ren Fail 2010;32:91-5.
32. Reis-Santos B, Gomes T, Horta BL, Maciel EL. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinomial analysis. J Bras Pneumol 39:585.
33. Sharma AP, Sural S, Gupta A et al. Effect of antitubercular medications on blood pressure control in chronic kidney disease patients with tuberculosis: a prospective cohort study. J Nephrol 2006;19:771-7.
34. Desai HN. Tuberculous pericarditis. A review of 100 cases. S Afr Med J 1979;55:877-80.
35. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation 2005;112:3608-16.
36. Reuter H, Burgess LJ, Doubell AF. Epidemiology of pericardial effusions at a large academic hospital in South Africa. Epidemiol Infect 2005;133:393-9.
37. Murray CJL, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
38. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
39. WHO, UNAID, UNICEF. Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access - Progress Report 2011. Geneva: World Health Organization; 2011. http://www.unaids.org/sites/default/files/media_asset/20111130_UA_Report_ en_1.pdf [accessed 1 December 2014].
40. Subbaraman R, Chaguturu SK, Mayer KH et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007;45:1093-1101.
41. Dillon DG, Gurdasani D, Riha J et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol 2013;42:1754-71.
42. Walker RW, Jusabani A, Aris E et al. Stroke risk factors in an incident population in urban and rural Tanzania: a prospective, community-based, case-control study. Lancet Glob Health 1:e282-8.
43. Butt AA, McGinnis K, Rodriguez-Barradas MC et al. HIV infection and the risk of diabetes mellitus. AIDS 2009;23:1227-34.
44. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179-84.
45. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008;31:1224-9.
46. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009;50:499-505.
47. Dave JA, Lambert EV, Badri M et al. Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr 2011;57:284-9.
48. Grunfeld C, Kotler DP, Hamadeh R et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27-31.
49. Montes ML, Pulido F, Barros C et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005;55:800-4.
50. Anastos K, Lu D, Shi Q et al. Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007;45:34-42.
51. Goedecke JH, Micklesfield LK, Levitt NS et al. Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. AIDS Res Hum Retroviruses 2013;29:557-63.
52. Thienemann F, Sliwa K, Rockstroh JK. HIVand the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J 2013;34:3538-46.
53. Twagirumukiza M, Nkeramihigo E, Seminega B et al. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res 2007;5:129-37.
54. Luo L, Ye Y, Liu Z et al. Assessment of cardiac diastolic dysfunction in HIV-infected people without cardiovascular symptoms in China. Int J STD AIDS 2010;21:814-8.
55. Sliwa K, Carrington MJ, Becker A et al. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012;33:866-74.
56. Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Africa 2012;23:90-7.
57. Thöni GJ, Schuster I, Walther G et al. Silent cardiac dysfunction and exercise intolerance in HIV+ men receiving combined antiretroviral therapies. AIDS 2008;22:2537-40.
58. Reinsch N, Kahlert P, Esser S et al. Echocardiographic findings and abnormalities in HIV-infected patients: results from a large, prospective, multicenter HIV-heart study. Am J Cardiovasc Dis 2011;1:176-84.
59. Degano B, Guillaume M, Savale L et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS 2010;24:67-75.
60. Young F, Critchley JA, Johnstone LK, Unwin NC. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Global Health 2009;5:9.
61. D:A:D Study GroupSabin CA, Worm SWet al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26.
62. Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228-38.
63. Monforte AD, Reiss P, Ryom L et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013;27:407-15.
64. Ding X, Andraca-Carrera E, Cooper C et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012;61:441-7.
65. Szczech LA, Gupta SK, Habash R et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004;66:1145-52.
66. Winston J, Deray G, Hawkins T et al. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008;47:1449-57.
67. Berns JS, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol 2006;1:117-29.
68. Hsieh M-H, Lu P-L, Kuo M-C et al. Prevalence of and associated factors with chronic kidney disease in human immunodeficiency virus-infected patients in Taiwan. J Microbiol Immunol Infect 2013; pii:S1684-1182(13)00158-8.check page numbers
69. Mizushima D, Tanuma J, Kanaya F et al. WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients. PLoS One 2013;8:e79885.
70. Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat 2011;2011:1-11.
71. Diaz PT, King MA, Pacht ER et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000;132:369-72.
72. O'Donnell CR, Bader MB, Zibrak JD et al. Abnormal airway function in individuals with the acquired immunodeficiency syndrome. Chest 1988;94:945-8.
73. Crothers K, Butt AA, Gibert CL et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006;130:1326-33.
74. Gingo MR, Balasubramani GK, Rice TB et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med 2014;14:75.
75. Madeddu G, Fois AG, Calia GM et al. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection 2012;41:347-53.
76. Makinson A, Hayot M, Eymard-Duvernay S et al. High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers. Eur Resp J 2014;pii: erj01549-2014.
77. High KP, Brennan-Ing M, Clifford DB et al. HIV and aging. J Acquir Immune Defic Syndr 2012;60:S1-18.
78. Yusuf AJ, Hassan A, Mamman AI et al. Prevalence of HIV-associated neurocognitive disorder (HAND) among patients attending a tertiary health facility in Northern Nigeria. J Int Assoc Provid AIDS Care 2014; pii: 23259557414553839.
79. Garg RK. HIV infection and seizures. Postgrad Med J 1999;75:387.
80. Satishchandra P, Sinha S. Seizures in HIV-seropositive individuals: NIMHANS experience and review. Epilepsia 2008;49:33-41.
81. Epilepsy and HIV-a dangerous combination. Lancet Neurol 2007;6:747.
82. Birbeck GL, French JA, Perucca E et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012;78:139-45.
83. Siddiqi O, Birbeck GL. Safe Treatment of seizures in the setting of HIV/AIDS. Curr Treat Options Neurol 2013;15:529-43.
84. WHO. Malaria: fact sheet no. 94. Geneva:World Health Organization; 2013.
85. Gething PW, Patil AP, Smith DL et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J 2011;10:378.
86. Tusting LS, Willey B, Lucas H et al. Socioeconomic development as an intervention against malaria: a systematic reviewand meta-analysis. Lancet 2013;382:963-72.
87. Perez-Escamilla R, Dessalines M, Finnigan M et al. Household food insecurity is associated with childhood malaria in rural Haiti. J Nutr 2009;139:2132-8.
88. Mitangala PN, D'Alessandro U, Donnen P et al. Malaria infection and nutritional status: results from a cohort survey of children from 6-59 months old in the Kivu province, Democratic Republic of the Congo. Rev Epidemiol Sante Publique 2013;61:111-20.
89. DeribewA, Alemseged F, Tessema F et al. Malaria and under-nutrition: a community based study among under-five children at risk of malaria, south-west Ethiopia. PLoS One 2010;5:e10775.
90. Crookston BT, Alder SC, Boakye I et al. Exploring the relationship between chronic undernutrition and asymptomatic malaria in Ghanaian children. Malar J 2010;9:39.
91. Danquah I, Bedu-Addo G, Mockenhaupt FP. Type 2 diabetes mellitus and increased risk for malaria infection. Emerg Infect Dis 2010;16:1601-4.
92. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-72.
93. White SL, Chadban SJ, Jan S et al. Howcan we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008;86:229-37.
94. Anand S, Bitton A, Gaziano T. The gap between estimated incidence of end-stage renal disease and use of therapy. PLoS One 2013;8: e72860.
95. Elsheikha HM, Sheashaa HA. Epidemiology, pathophysiology, management and outcome of renal dysfunction associated with plasmodia infection. Parasitol Res 2007;101:1183-90.
96. NICE. Malaria prophylaxis. London: National Institute for Health and Care Excellence; 2012. http://cks.nice.org.uk/malaria-prophylaxis [accessed 15 December 2014].
97. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev 2007;20:579-92.
98. Oni T, Youngblood E, Boulle A et al. Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa- a cross sectional study. BMC Infect Dis 2015;15:20.
99. WHO. Diabetes Programme. Innovative care for chronic conditions: Building blocks for action: WHO global report 2002. Geneva: World Health Organization; 2002. http://www.who.int/diabetes/publications/icccreport/en/[accessed 1 December 2014].
100. Oni T, McGrath N, BeLue R et al. Chronic diseases and multi-morbidity - a conceptual modification to the WHO ICCC model for countries in health transition. BMC Public Health 2014;14:575.
101. WHO. Global Status Report on Non-Communicable Diseases 2010. Geneva: World Health Organization; 2011. http://www.who.int/nmh/publications/ncd_report_full_en.pdf [accessed 20 January 2015].
102. WHO. Global Health and Aging. Geneva: World Health Organization; 2011. http://www.who.int/ageing/publications/global_health.pdf [accessed 20 January 2015].
103. Holmes WR, Joseph J. Social participation and healthy ageing: a neglected, significant protective factor for chronic non communicable conditions. Global Health 2011;7:43.